炎症性肠病合并特殊共患病的研究现状

杨红; 钱家鸣

doi:10.3969/j.issn.1001-5256.2020.07.001

炎症性肠病合并特殊共患病的研究现状

DOI: 10.3969/j.issn.1001-5256.2020.07.001

杨红,
钱家鸣

中国医学科学院，北京协和医学院，北京协和医院消化科

基金项目:

公益性行业科研专项项目(201002020,201502005)；中国医学科学院医学与健康科技创新工程基金(CIFMS,2016-12M-3-001,2019-1002-71)；

详细信息

中图分类号: R574
计量
- 文章访问数: 1453
- HTML全文浏览量: 38
- PDF下载量: 242
- 被引次数: 0
出版历程
- 出版日期: 2020-07-20

Current status of research on inflammatory bowel disease with special comorbidities

Chinese Academy of Medical Sciences; Peking Union Medical College; Department of Gastroenterology, Peking Union Medical College Hospital, Beijing 100730, China

Research funding:

摘要

摘要:
炎症性肠病(IBD)不仅仅会发生肠道受累,还常常会出现一些肠外的共患疾病,其中IBD合并的特殊共患病涉及多类疾病,包括血液系统疾病、免疫系统疾病、神经系统疾病等。IBD合并特殊共患病增加了IBD诊断和处理的难度,也会增加IBD患者的致残率和死亡率,严重影响生活质量。阐述了IBD合并特殊共患病的定义、流行趋势、发病机制和诊治策略,期望提高临床医生对IBD诊治多学科合作重要性的理解。
- 炎症性肠病 /
- 共患病 /
- 胆管炎,硬化性 /
- 肝炎,自身免疫性
Abstract:
Inflammatory bowel disease(IBD) not only involves the intestinal tract,but also has several comorbidities outside the intestinal tract,among which there are various types of special comorbidities,including hematological system diseases,immune system diseases,and nervous system diseases. IBD with special comorbidities brings difficulties to the diagnosis and treatment of IBD,increases the disability rate and mortality rate of IBD patients,and greatly affects patients' quality of life. This article elaborates on the definition,prevalence trend,pathogenesis,and diagnosis and treatment strategies for IBD with special comorbidities,in order to improve the understanding of the importance of multidisciplinary cooperation in the diagnosis and treatment of IBD among clinicians.
- inflammatory bowel disease /
- cholangitis,sclerosing /
- hepatitis,autoimmune /

HTML全文

参考文献(17)

[1]KAPLAN GG,NG SC.Understanding and preventing the global increase of inflammatory bowel disease[J].Gastroenterology,2017,152(2):313-321.e2．

[2]WILSON JC,FURLANO RI,JICK SS,et al.Inflammatory bowel disease and the risk of autoimmune diseases[J].J Crohns Colitis,2016,10(2):186-193．

[3]VAVRICKA SR,FURLANO RI,JICK SS,et al.Extraintestinal manifestations of inflammatory bowel disease[J].Inflamm Bowel Dis,2015,21(8):1982-1992．

[4]ROTHFUSS KS,STANGE EF,HERRLINGER KR.Extraintestinal manifestations and complications in inflammatory bowel diseases[J].World J Gastroenterol,2006,12(30):4819-4831．

[5] HARBORD M,ANNESE V,VAVRICKA SR,et al.The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease[J].J Crohns Colitis,2016,10(3):239-254．

[6]LEES CW,BARRETT JC,PARKES M,et al.New IBD genetics:Common pathways with other diseases[J].Gut,2011,60(12):1739-1753．

[7]HEDIN CRH,VAVRICKA SR,STAGG SJ,et al.The pathogenesis of extraintestinal manifestations:Implications for IBD research,diagnosis,and therapy[J].J Crohns Colitis,2019,13(5):541-554．

[8]SHAH SC,TEN HOVE JR,CASTANEDA D,et al.High risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis associated with inflammatory bowel disease[J].Clin Gastroenterol Hepatol,2018,16(7):1106-1113.e3．

[9]PENG T,LIU YL.Inflammatory bowel disease with myelodysplastic syndrome:An analysis of 9 cases and literature review[J].Chin J Intern Med,2010,49(11):967-968.(in Chinese)彭涛，刘玉兰．炎症性肠病合并骨髓增生异常综合征九例分析并文献复习[J]．中华内科杂志，2010,49(11):967-968．

[10]HAREWOOD GC,LOFTUS EV Jr,TEFFERI A,et al.Concurrent inflammatory bowel disease and myelodysplastic syndromes[J].Inflamm Bowel Dis,1999,5(2):98-103．

[11]FENG Y,LIU YL.Progress of the extraintestinal manifestations of inflammatory bowel disease[J].Chin J Gastroenterol Hepatol,2015,24(6):631-640.(in Chinese)冯云，刘玉兰．炎症性肠病的肠外表现的研究进展[J]．胃肠病学和肝病学杂志，2015,24(6):631-640．

[12]UEKI T,KAWAMOTO K,OTSUKA Y,et al.Prevalence and clinicopathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease[J].Pancreas,2015,44(3):434-440．

[13]HALLING ML,KJELDSEN J,KNUDSEN T,et al.Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases[J].World J Gastroenterol,2017,23(33):6137-6146．

[14]UHLIG HH,MUISE AM.Clinical genomics in inflammatory bowel disease[J].Trends Genet,2017,33(9):629-641．

[15]MCGOVERN DP,KUGATHASAN S,CHO JH.Genetics of inflammatory bowel diseases[J].Gastroenterology,2015,149(5):1163-1176.e2．

[16] LI J,WEI MM,FEI GJ,et al.The efficacy of cyclosporine A as salvage therapy for severe active ulcerative colitis refractory to glucocorticoid[J].Chin J Intern Med,2017,56(4):279-283.(in Chinese)李骥，韦明明，费贵军，等．环孢素A治疗糖皮质激素抵抗的重度溃疡性结肠炎疗效观察[J]．中华内科杂志，2017,56(4):279-283．

[17]WEISSMAN S,CHRIS-OLAIYA A,MEHTA TI,et al.A novel player:Cyclosporine therapy in the management of inflammatory bowel disease[J].Transl Gastroenterol Hepatol,2019,4:67.

施引文献

资源附件(0)

访问统计